Fig. 6

In vivo efficacy of S1g-2 in xenograft models of MCF-7/TAM-R. A Tumor volume curve after treatment with 0.8 mg/kg S1g-2. The data are plotted as the means ± SEM (n = 5 mice for each group). B Tumors isolated from vehicle- and S1g-2-treated groups (n = 5), respectively, at the end of treatment. C The mouse body weight during the treatment period. The data are plotted as the means ± SEM (n = 5 mice for each group). D Representative H&E stainning of liver and Kidney tissues from vehicle- and S1g-2-treated groups (n = 5), respectively. E Western blot and co-IP analysis of the xenograft tumors derived from vehicle- and S1g-2-treated groups. The graphs show (mean ± SD, n = 3 biologically independent experiments) Bim, ERα36 and ERα66 protein level in Hsp70 co-IP and cell lysates in S1g-2-treated groups normalized against β-actin and relative to that in vehicle-treated groups. *P < 0.05, **P < 0.01 (one-way ANOVA test); n.s. indicates no significance between vehicle- and S1g-2-treated groups. F Tumors were sectioned and subsequently stained with H&E (left panels) or TUNEL (middle panels) with white light imaging (right panels)